Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/2/2011

on partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials, the announcement of clinical trial results, and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care,  evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeuti
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today ... Board of Directors, effective September 15, 2014. Dr. Raths, ... as its placement agent to market a private preferred ... and early stroke treatment. "Jurgen,s deep experience ... be a great asset to Vesselon as we develop ...
(Date:9/23/2014)... DALLAS , September 23, 2014 ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to ... Market over the forecast period of 2014 to ... Billion by 2019, at CAGR of 9.6% from ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
... May 10 Par Pharmaceutical Companies, Inc. (NYSE: ... Generics Limited and Glenmark Generics Inc., USA , has ... that resolves patent litigation related to Glenmark,s challenge to Merck,s ... involving a challenge by Glenmark which sought to launch a ...
Cached Medicine Technology:CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
(Date:9/23/2014)... with its advances promises of individualized genetic information ... Genetic tests are already guiding treatments of ... virus (HPC), and emerging research is showing genetic ... individual,s susceptibility to addiction to a substance, and ... appear to be many benefits inherent in the ...
(Date:9/23/2014)... Washington, DC (PRWEB) September 23, 2014 ... affordable care? The National Quality Forum (NQF) ... sheet ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( ... the rising cost of healthcare, how patients define ... for consumers to get the best possible healthcare ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... revealed that women do not put on weight as a ... center said that the belief weight is gained as a ... such beliefs// are not based on facts. ... over the past few years that examined the effects of ...
... predisposed where smoking is concerned, according to a new research. ... habit. A gene which is called CYP2A6 serves to regulate ... for smoking addiction. ,People carry different forms ... particular parts of the world, and the Asiatic people show ...
... in the functioning of the heart with the progress of age ... according to a study which the Journal of the American College ... goes to show that primary aging can // be delayed by ... ,This fact has already been proved in the ...
... A DNA study conducted at the burial pits of ancient ... large-scale devastation to the city. The Golden Age of Athens ... this // epidemic, which is said to have wiped out ... epidemic was in Ethiopia, between 430-426 BC, which later spread ...
... dish ‘Haggis’ had an increased fat diet which the officials ... are now facing a high risk of getting obese and ... Haggis not more than once in a week. ... liver and heart of sheep which is mixed with oatmeal ...
... herbs along with conventional medical treatment for severe acute respiratory ... life// of such victims, according to latest reports. It may ... margin. ,The researchers of the present study ... of 654 SARS patients, treated with both allopathic and Chinese ...
Cached Medicine News: